Do SARMs really suppress the HPG axis?

Yes, at effective doses. The 'non-suppressive SARM' myth is widely spread on internet but contradicted by clinical data. Dalton 2011 documents a testosterone decrease as early as 3 mg/d of Ostarine; at 25 mg/d (bodybuilding dose), suppression reaches 30-50% of baseline. Basaria 2013 confirms dose-dependent suppression on LGD-4033. Bhasin 2009 (SARM function-promoting review) specifies that all AR agonists at anabolic doses suppress the HPG axis via hypothalamic feedback. Practical consequence: PCT required for all effective SARM cycles.

What PCT after a SARMs cycle?

Depends on the SARM and dose. For Ostarine 25 mg/d for 8 wk: Nolvadex 20 mg/d for 4 wk suffices in most. For LGD-4033 10 mg/d for 8 wk or RAD-140 10 mg/d for 8 wk: Nolvadex 40/40/20/20 mg/d for 4 wk, sometimes + Clomid 50/50/25/25 mg/d in parallel. For SARMs stacks (LGD + Ostarine or RAD + Ostarine): moderate AAS-type PCT (Nolva + Clomid 4 wk). Bloodwork total T + LH 6 wk post-PCT to confirm recovery. hCG very rarely needed on SARMs cycles (HPG axis less deeply suppressed than on heavy AAS stacks).

Are SARMs safer than AAS?

Not demonstrated in 2026. SARMs long-term safety profile is largely unknown: phase 2/3 human studies are limited (Dalton 2011 the most solid, over 12 wk). AAS are disliked but well-studied (Bhasin 1996, Hartgens 2004, HAARLEM Smit 2021/2022). SARMs accumulate risks: (1) highly variable market quality (frequent counterfeits — Magnolini 2022), (2) documented hepatotoxicity (elevated ALT/AST on RAD-140 and LGD-4033), (3) degraded lipid profile, (4) absent long-term data. 'Safer' argument often rests on lower dose vs AAS, not on clinical evidence.

Black-market SARMs: how to verify quality?

Difficult. Magnolini 2022 (spectrometric analysis of European AAS products) documents 40-60% non-compliant products; for SARMs, recent analyses (Almeida 2021, Van Wagoner 2017 USA) suggest 50-70% out-of-spec products. Risk-reduction strategies: (1) Third-party analysis (HPLC, MS) by labs like JANO, AnalyticalGroup, Aramo (~$50-100/sample). (2) Sources with public batch testing and verifiable reviews. (3) Distrust of 'generic' products without certificate. (4) For personal use: test on first SARMs cycle with mid-cycle total T bloodwork to confirm real activity. No absolute guarantee.

SARMs and anti-doping: risk?

High. All SARMs are on the WADA list (S1.2 category — other anabolic agents) banned in and out of competition. Detection: Ostarine, LGD-4033, RAD-140 detectable up to 2-6 months post-stop depending on dose and test (Solomon 2019). Documented cases of 'accidental' contamination via SARMs-contaminated supplements (growing problem 2018-2024). Tested-sport athletes must avoid even non-batch-tested supplements. Variable civil legal status: in many regions, SARMs are in a gray zone (neither MA nor cosmetic authorization), marketed as 'research chemicals' with 'not for human consumption' label.

Is an AI needed on a SARMs cycle?

Rarely. Most SARMs don't aromatize (no E2 conversion). However, endogenous testosterone early in cycle may still aromatize; and certain SARMs (Ostarine in particular) may indirectly modulate SHBG. Recommendation: no routine AI on SARMs cycles. If elevated E2 symptoms (nascent gynecomastia, retention), E2 bloodwork and anastrozole 0.25 mg E3D as needed. On SARM stop, E2 may transiently rebound — manage during PCT if necessary.

Do SARMs preserve mass during cutting?

Yes, modestly. Ostarine 12.5-25 mg/d for 8 wk in caloric deficit preserves lean mass better than without SARM, by direct anti-catabolic effect on muscle (mechanism close to AAS without peripheral androgenicity). Solomon 2019 review documents Ostarine anti-catabolic effect in sarcopenia/cachexia. On athlete at -400 kcal/d for 8 wk: mass preservation +0.5 to +1 kg vs natural or +1-2 kg vs without SARM. Effect more modest than Test E + Anavar cycle but without injection, null androgenic profile, and moderate cost.

Is MK-677 dangerous for diabetes?

To monitor. MK-677 increases GH and IGF-1, which may induce moderate insulin resistance — Nass 2008 documents elevated fasting glucose in elderly subjects on MK-677 at 25 mg/d. Reversible effect on stop. Recommendations: fasting glucose monitoring at W4, W8, W12; HbA1c at start and end of cycle. Contraindicated in: pre-diabetics (HbA1c >5.7%), type 2 diabetics, strong family history. Possible in subject with normal baseline glucose with monitoring. Precaution: no fast carbohydrates in evening, exercise maintained for insulin sensitivity.

Best SARM stacks in 2026 — 10 protocols ranked (research)

Methodology

Rankings based on 4 weighted criteria for SARMs. (1) Clinical data profile: number and quality of available human studies (RCT > phase 2 > preclinical), prioritizing molecules that have advanced to human clinical trials vs only preclinical. (2) HPG suppression profile: extent of LH/FSH suppression at effective dose, average recovery duration. (3) Hepatic and lipid safety profile: ALT/AST, HDL, LDL (Basaria 2013 on LGD-4033, Solomon 2019 review). (4) Market availability and quality: rate of authentic products, documented suppliers, counterfeit risks. Critical warning: no SARM has marketing authorization in 2026; all uses remain experimental outside clinical trials. The dosages mentioned are indicative based on partial literature and non-standardized user feedback. Primary sources: Dalton 2011 (enobosarm phase 2), Basaria 2013 (LGD-4033 safety phase 1), Bhasin 2009 (SARM function-promoting), Solomon 2019 (SARM clinical applications review), Miller 2010 (RAD140 preclinical), Gao 2005 (andarine preclinical).

1. Ostarine (MK-2866) 25 mg/d for 8 wk — the best-studied SARM
Ostarine (enobosarm) is the best clinically documented SARM: Dalton 2011 (phase 2, 12 wk, 159 elderly subjects) at 3 mg/d demonstrated +1.3 kg lean mass vs placebo. At 25 mg/d (bodybuilding dose), expected gains +2-4 kg lean mass. Moderate but significant HPG suppression (LH/FSH lowered 30-50% at 25 mg/d). Bhasin 2009 and Solomon 2019 frame potential clinical use (sarcopenia, cancer cachexia).
Dose / Duration
Ostarine 12.5-25 mg/d single morning dose for 6-8 wk. Low start (12.5 mg/d for 1 wk) then ramp. PCT Nolvadex 20 mg/d for 4 wk post-stop.
Target audience
Informed researchers accepting SARMs risk profile, first monotherapy attempt to evaluate individual response, seeking a light anabolic effect without injection.
Pros
- + Best clinically documented SARM (Dalton 2011)
- + Moderate HPG suppression vs other SARMs
- + Joint preservation (collagen)
- + No aromatization, no DHT
- + Moderate cost (~$80-150 for 8 wk)
Cons
- − Black market: high counterfeit rate
- − Real HPG suppression at 25 mg/d ("non-suppressive" myth)
- − Minor liver risk (ALT/AST elevations possible)
- − Modest gains vs AAS (+2-4 kg)
- − Unclear legal status (research chemical, WADA-banned)
2. LGD-4033 (Ligandrol) 5-10 mg/d for 6-8 wk — the powerful SARM
LGD-4033 is one of the most potent SARMs per milligram. Basaria 2013 (phase 1, 21 young subjects, 21 days) documented at 1 mg/d +1.2 kg lean mass without major adverse effects; at bodybuilding doses (5-10 mg/d), expected gains +3-5 kg with marked HPG suppression (total T ~50% of baseline). Liver moderately affected in some subjects.
Dose / Duration
LGD-4033 5-10 mg/d single morning dose for 6-8 wk. Start 5 mg/d for 2 wk then 10 mg/d. PCT Nolva 40/40/20/20 for 4 wk or Nolva + Clomid if high dose.
Target audience
SARM users with prior Ostarine experience, seeking a more marked anabolic effect, solid baseline liver and lipids. Not as first SARM attempt.
Pros
- + Among the most marked anabolic effects of SARMs
- + Documented gains (Basaria 2013 phase 1)
- + Modest mg doses (5-10 mg/d)
- + Notable strength effect
- + Relatively accessible cost
Cons
- − Marked HPG suppression at 10 mg/d
- − Degraded lipid profile (HDL drop)
- − Possible ALT/AST elevations
- − Long human studies still limited
- − Black market: highly variable quality
3. RAD-140 (Testolone) 10 mg/d for 6-8 wk — the "test-like" SARM
RAD-140 is the most 'testosterone-like' SARM by anabolic profile. Miller 2010 (preclinical) documented a theoretically very favorable anabolic:androgenic ratio in rodents. Limited human studies (oncology phase 1). At bodybuilding doses (10 mg/d), reported gains +3-5 kg lean mass with strong HPG suppression (equivalent to Test E 200-300 mg/wk).
Dose / Duration
RAD-140 10 mg/d single dose for 6-8 wk. Start 5 mg/d for 1 wk. PCT Nolva 40/40/20/20 for 4 wk + Clomid if needed. Hepatoprotectors.
Target audience
Very advanced SARM users, solid baseline, prior Ostarine and LGD experience, acceptance of undocumented long-term risk profile. Not as first or second SARM attempt.
Pros
- + Among the most powerful anabolic effects of SARMs
- + Notable strength and aggression effect
- + Solid preclinical studies (Miller 2010)
- + Modest mg doses
- + Often perceived as 'SARM for advanced'
Cons
- − Very marked HPG suppression (equivalent Test 200-300 mg/wk)
- − Phase 1 oncology human studies only
- − Sometimes marked aggression profile
- − Degraded lipid profile
- − Black market: RAD-140 often counterfeited
4. Stack Ostarine + Cardarine (25 mg + 20 mg/d for 8 wk) — the recomposition stack
Combines Ostarine (light anabolic) + Cardarine GW-501516 (PPARδ agonist, lipolytic and endurance). Cardarine is not a SARM but a PPARδ activator (Narkar 2008 — exercise mimetic). Popular stack for light recomposition (muscle gain + fat loss). Cardarine controversy: Mitchell 2019 raised carcinogenic risk in rodents at high doses (human extrapolation debated).
Dose / Duration
Ostarine 25 mg/d + Cardarine 10-20 mg/d for 8-10 wk. PCT Nolva 20-40 mg/d for 4 wk for Ostarine suppression. Cardarine stop 1 wk before PCT.
Target audience
Intermediate SARM users accepting cardarine risk profile, seeking a light recomposition effect, profiles without family oncological history. Informed decision.
Pros
- + Possible recomposition: mass + cutting
- + Cardarine does not suppress HPG
- + Improved endurance (useful cardio)
- + Marked lipolytic effect
- + Moderate cost
Cons
- − Debated cardarine carcinogenic risk (Mitchell 2019)
- − HPG suppression by Ostarine
- − Black-market cardarine: highly variable quality
- − Almost non-existent human cardarine studies
- − Strict WADA ban
5. Stack LGD + Ostarine (10 + 25 mg/d for 8 wk) — the SARM mass stack
Combines LGD-4033 (powerful anabolic) + Ostarine (moderate anabolic, anti-catabolic). Popular stack for SARM mass cycle. Theoretical synergy on androgen receptor. Expected gains +4-6 kg lean mass with significant cumulative HPG suppression. No clinical studies of the combination; profile based on extrapolations.
Dose / Duration
LGD-4033 10 mg/d + Ostarine 25 mg/d for 8 wk. PCT Nolva 40/40/20/20 + Clomid 50/50/25/25 for 4 wk. Hepatoprotectors.
Target audience
Very advanced SARM users, seeking an alternative to injectable AAS, solid baseline liver. Informed decision accepting undocumented cumulative risks.
Pros
- + More marked potential gains (+4-6 kg)
- + Androgen receptor synergy
- + Joint preservation (Ostarine)
- + Notable strength effect
- + No injection
Cons
- − Major cumulative HPG suppression
- − Degraded lipid and liver profile
- − No clinical studies of the combination
- − Black market: variable quality of 2 products
- − Demanding PCT
6. Stack RAD-140 + Ostarine (10 + 20 mg/d for 8 wk) — the "mass strength" stack
Combines RAD-140 ('test-like' anabolic + strength and aggression effect) + Ostarine (anti-catabolic, joint preservation). Stack oriented toward SARM powerlifting/strongman version. Expected gains +4-6 kg with notable strength gain. Very marked HPG suppression (equivalent Test E 200-300 mg/wk + Ostarine 25 mg).
Dose / Duration
RAD-140 10 mg/d + Ostarine 20 mg/d for 8 wk. PCT Nolva 40/40/20/20 + Clomid 50/50/25/25 for 4 wk. Continuous hepatoprotectors.
Target audience
Very advanced SARM users in strength or powerlifting phase, solid baseline, acceptance of undocumented risk profile. Not for anxious users or those with psychiatric history.
Pros
- + Record strength effect
- + Recomposition possible
- + Joint preservation (Ostarine)
- + Positive gym aggression
- + No injection
Cons
- − Severe HPG suppression
- − Very degraded lipid profile
- − Probable ALT/AST elevations
- − Sometimes excessive aggression (daily life)
- − Combination human studies absent
7. S4 (Andarine) 50 mg/d for 6 wk — the "dry" SARM
S4 (Andarine) is an older SARM (Gao 2005 preclinical) with marked 'dry' effect and low aromatization. Visual effect appreciated for cutting. Major drawback: documented visual side effect (yellowish vision, night disturbances) at 50-75 mg/d, reversible on stop. Very limited human clinical studies.
Dose / Duration
S4 50 mg/d in 2 doses (morning/noon) for 6 wk. PCT Nolva 20 mg/d for 4 wk. Pause if visual disturbances appear.
Target audience
Intermediate SARM users in cutting phase, accepting transient visual disturbances, no ophthalmological history. Not for night drivers or visual-precision jobs.
Pros
- + Marked "dry" visual effect
- + Low aromatization
- + Moderate cost
- + Mass preservation in deficit
- + No DHT
Cons
- − Documented visual disturbances (yellowish night vision)
- − Very limited human studies
- − Preclinical studies only (Gao 2005)
- − Short half-life — 2 doses/day
- − Black market: variable quality
8. YK-11 5-10 mg/d for 6 wk — the "myostatin inhibitor"
YK-11 is an atypical SARM with partial AR agonist mechanism and documented preclinical myostatin inhibitor (Kanno 2011, Kanno 2013). Theoretically 'hyper' anabolic effect by lifting the myostatin brake. No human studies. Liver probably more toxic than classic SARMs. Very experimental profile.
Dose / Duration
YK-11 5-10 mg/d in 2 doses (short half-life) for 6-8 wk. PCT Nolva 40/40/20/20 for 4 wk. Continuous hepatoprotectors.
Target audience
Very advanced researchers, accepting total absence of human clinical data, excellent baseline liver, close bio monitoring. Very informed decision required.
Pros
- + Unique mechanism (myostatin inhibition)
- + Powerful theoretical anabolic effect
- + Solid preclinical studies (Kanno 2011, 2013)
- + Modest doses (5-10 mg/d)
- + Marked visual effect
Cons
- − No human studies
- − Probably hepatotoxic (17α-methylated steroid structure)
- − Unknown HPG suppression profile
- − Black market: very variable
- − Very unclear legal and scientific status
9. S23 10-25 mg/d for 6-8 wk — the "hard" SARM
S23 is an experimental SARM with very high AR affinity. Jones 2009 (preclinical in male rats) documented its potential as male contraceptive. Marked 'hard' and dry effect in users. Human studies absent. Severe HPG suppression and very degraded lipid profile.
Dose / Duration
S23 10-25 mg/d for 6-8 wk. PCT Nolva 40/40/20/20 + Clomid 50/50/25/25 for 4 wk.
Target audience
Very few defensible indications in 2026. Reserved for researchers accepting total absence of human data. Very poorly informed decision by default.
Pros
- + Very high AR affinity
- + Marked "dry" effect
- + Preclinical contraceptive study (Jones 2009)
- + Notable strength effect
- + No aromatization
Cons
- − No human studies
- − Severe HPG suppression
- − Very degraded lipid profile
- − Black market: unverifiable quality
- − Unknown long-term risks
10. MK-677 (Ibutamoren) 25 mg/d for 12 wk — the "oral SARM" GH
MK-677 is not a SARM but an oral GH secretagogue (ghrelin mimetic, Bowers 1984, Kojima 1999). Stimulates GH and IGF-1 release via GHS-R receptor. Nass 2008 (RCT phase 2, 65 elderly subjects, 2 years) documented +1.1 kg lean mass at 25 mg/d. Often stacked with SARMs for recovery and gain quality. Marked effects on appetite, sleep and glucose.
Dose / Duration
MK-677 25 mg/d single evening dose for 8-16 wk. No specific PCT (not HPG-suppressive). Fasting glucose monitoring.
Target audience
SARM or AAS users seeking GH/IGF-1 support, improved recovery, deep sleep. Not for pre-diabetics or those with strong family oncological history.
Pros
- + No HPG suppression
- + Solid human clinical studies (Nass 2008)
- + Marked deep sleep effect
- + Improved recovery
- + Compatible with all cycles
Cons
- − Strongly increased appetite (water retention)
- − Disturbed fasting glucose (moderate insulin resistance)
- − Early-cycle lethargy
- − Elevated IGF-1 — theoretical oncological risk (Renehan 2008)
- − Moderate-high cost

Final comparison

Protocol	Gains 8 wk	HPG suppression	Safety	PCT
Ostarine solo	+2-4 kg	Moderate	Best SARM	Simple
LGD-4033 solo	+3-5 kg	Marked	Medium	Medium
RAD-140 solo	+3-5 kg	Severe	Medium-low	Medium
Ostarine + Cardarine	+2-3 kg + fat loss	Moderate	Cardarine controversial	Simple
LGD + Ostarine	+4-6 kg	Severe	Medium-low	Demanding
RAD + Ostarine	+4-6 kg	Very severe	Low	Demanding
S4 (Andarine)	+1-2 kg + hardness	Moderate	Visual disturbances	Simple
YK-11	+2-4 kg (?)	Unknown	Hepatic questionable	Medium
S23	+3-5 kg (?)	Severe	Very experimental	Demanding
MK-677	+1-2 kg + recovery	None	Good apart from glucose	None

FAQ

Do SARMs really suppress the HPG axis?: Yes, at effective doses. The 'non-suppressive SARM' myth is widely spread on internet but contradicted by clinical data. Dalton 2011 documents a testosterone decrease as early as 3 mg/d of Ostarine; at 25 mg/d (bodybuilding dose), suppression reaches 30-50% of baseline. Basaria 2013 confirms dose-dependent suppression on LGD-4033. Bhasin 2009 (SARM function-promoting review) specifies that all AR agonists at anabolic doses suppress the HPG axis via hypothalamic feedback. Practical consequence: PCT required for all effective SARM cycles.
What PCT after a SARMs cycle?: Depends on the SARM and dose. For Ostarine 25 mg/d for 8 wk: Nolvadex 20 mg/d for 4 wk suffices in most. For LGD-4033 10 mg/d for 8 wk or RAD-140 10 mg/d for 8 wk: Nolvadex 40/40/20/20 mg/d for 4 wk, sometimes + Clomid 50/50/25/25 mg/d in parallel. For SARMs stacks (LGD + Ostarine or RAD + Ostarine): moderate AAS-type PCT (Nolva + Clomid 4 wk). Bloodwork total T + LH 6 wk post-PCT to confirm recovery. hCG very rarely needed on SARMs cycles (HPG axis less deeply suppressed than on heavy AAS stacks).
Are SARMs safer than AAS?: Not demonstrated in 2026. SARMs long-term safety profile is largely unknown: phase 2/3 human studies are limited (Dalton 2011 the most solid, over 12 wk). AAS are disliked but well-studied (Bhasin 1996, Hartgens 2004, HAARLEM Smit 2021/2022). SARMs accumulate risks: (1) highly variable market quality (frequent counterfeits — Magnolini 2022), (2) documented hepatotoxicity (elevated ALT/AST on RAD-140 and LGD-4033), (3) degraded lipid profile, (4) absent long-term data. 'Safer' argument often rests on lower dose vs AAS, not on clinical evidence.
Black-market SARMs: how to verify quality?: Difficult. Magnolini 2022 (spectrometric analysis of European AAS products) documents 40-60% non-compliant products; for SARMs, recent analyses (Almeida 2021, Van Wagoner 2017 USA) suggest 50-70% out-of-spec products. Risk-reduction strategies: (1) Third-party analysis (HPLC, MS) by labs like JANO, AnalyticalGroup, Aramo (~$50-100/sample). (2) Sources with public batch testing and verifiable reviews. (3) Distrust of 'generic' products without certificate. (4) For personal use: test on first SARMs cycle with mid-cycle total T bloodwork to confirm real activity. No absolute guarantee.
SARMs and anti-doping: risk?: High. All SARMs are on the WADA list (S1.2 category — other anabolic agents) banned in and out of competition. Detection: Ostarine, LGD-4033, RAD-140 detectable up to 2-6 months post-stop depending on dose and test (Solomon 2019). Documented cases of 'accidental' contamination via SARMs-contaminated supplements (growing problem 2018-2024). Tested-sport athletes must avoid even non-batch-tested supplements. Variable civil legal status: in many regions, SARMs are in a gray zone (neither MA nor cosmetic authorization), marketed as 'research chemicals' with 'not for human consumption' label.
Is an AI needed on a SARMs cycle?: Rarely. Most SARMs don't aromatize (no E2 conversion). However, endogenous testosterone early in cycle may still aromatize; and certain SARMs (Ostarine in particular) may indirectly modulate SHBG. Recommendation: no routine AI on SARMs cycles. If elevated E2 symptoms (nascent gynecomastia, retention), E2 bloodwork and anastrozole 0.25 mg E3D as needed. On SARM stop, E2 may transiently rebound — manage during PCT if necessary.
Do SARMs preserve mass during cutting?: Yes, modestly. Ostarine 12.5-25 mg/d for 8 wk in caloric deficit preserves lean mass better than without SARM, by direct anti-catabolic effect on muscle (mechanism close to AAS without peripheral androgenicity). Solomon 2019 review documents Ostarine anti-catabolic effect in sarcopenia/cachexia. On athlete at -400 kcal/d for 8 wk: mass preservation +0.5 to +1 kg vs natural or +1-2 kg vs without SARM. Effect more modest than Test E + Anavar cycle but without injection, null androgenic profile, and moderate cost.
Is MK-677 dangerous for diabetes?: To monitor. MK-677 increases GH and IGF-1, which may induce moderate insulin resistance — Nass 2008 documents elevated fasting glucose in elderly subjects on MK-677 at 25 mg/d. Reversible effect on stop. Recommendations: fasting glucose monitoring at W4, W8, W12; HbA1c at start and end of cycle. Contraindicated in: pre-diabetics (HbA1c >5.7%), type 2 diabetics, strong family history. Possible in subject with normal baseline glucose with monitoring. Precaution: no fast carbohydrates in evening, exercise maintained for insulin sensitivity.

Best SARM stacks in 2026 — 10 protocols ranked (research)

Methodology

1. Ostarine (MK-2866) 25 mg/d for 8 wk — the best-studied SARM

Ostarine (enobosarm) is the best clinically documented SARM: Dalton 2011 (phase 2, 12 wk, 159 elderly subjects) at 3 mg/d demonstrated +1.3 kg lean mass vs placebo. At 25 mg/d (bodybuilding dose), expected gains +2-4 kg lean mass. Moderate but significant HPG suppression (LH/FSH lowered 30-50% at 25 mg/d). Bhasin 2009 and Solomon 2019 frame potential clinical use (sarcopenia, cancer cachexia).

Dose / Duration

Ostarine 12.5-25 mg/d single morning dose for 6-8 wk. Low start (12.5 mg/d for 1 wk) then ramp. PCT Nolvadex 20 mg/d for 4 wk post-stop.

Target audience

Informed researchers accepting SARMs risk profile, first monotherapy attempt to evaluate individual response, seeking a light anabolic effect without injection.

Pros

+ Best clinically documented SARM (Dalton 2011)
+ Moderate HPG suppression vs other SARMs
+ Joint preservation (collagen)
+ No aromatization, no DHT
+ Moderate cost (~$80-150 for 8 wk)

Cons

− Black market: high counterfeit rate
− Real HPG suppression at 25 mg/d ("non-suppressive" myth)
− Minor liver risk (ALT/AST elevations possible)
− Modest gains vs AAS (+2-4 kg)
− Unclear legal status (research chemical, WADA-banned)

2. LGD-4033 (Ligandrol) 5-10 mg/d for 6-8 wk — the powerful SARM

LGD-4033 is one of the most potent SARMs per milligram. Basaria 2013 (phase 1, 21 young subjects, 21 days) documented at 1 mg/d +1.2 kg lean mass without major adverse effects; at bodybuilding doses (5-10 mg/d), expected gains +3-5 kg with marked HPG suppression (total T ~50% of baseline). Liver moderately affected in some subjects.

Dose / Duration

LGD-4033 5-10 mg/d single morning dose for 6-8 wk. Start 5 mg/d for 2 wk then 10 mg/d. PCT Nolva 40/40/20/20 for 4 wk or Nolva + Clomid if high dose.

Target audience

SARM users with prior Ostarine experience, seeking a more marked anabolic effect, solid baseline liver and lipids. Not as first SARM attempt.

Pros

+ Among the most marked anabolic effects of SARMs
+ Documented gains (Basaria 2013 phase 1)
+ Modest mg doses (5-10 mg/d)
+ Notable strength effect
+ Relatively accessible cost

Cons

− Marked HPG suppression at 10 mg/d
− Degraded lipid profile (HDL drop)
− Possible ALT/AST elevations
− Long human studies still limited
− Black market: highly variable quality

3. RAD-140 (Testolone) 10 mg/d for 6-8 wk — the "test-like" SARM

RAD-140 is the most 'testosterone-like' SARM by anabolic profile. Miller 2010 (preclinical) documented a theoretically very favorable anabolic:androgenic ratio in rodents. Limited human studies (oncology phase 1). At bodybuilding doses (10 mg/d), reported gains +3-5 kg lean mass with strong HPG suppression (equivalent to Test E 200-300 mg/wk).

Dose / Duration

RAD-140 10 mg/d single dose for 6-8 wk. Start 5 mg/d for 1 wk. PCT Nolva 40/40/20/20 for 4 wk + Clomid if needed. Hepatoprotectors.

Target audience

Very advanced SARM users, solid baseline, prior Ostarine and LGD experience, acceptance of undocumented long-term risk profile. Not as first or second SARM attempt.

Pros

+ Among the most powerful anabolic effects of SARMs
+ Notable strength and aggression effect
+ Solid preclinical studies (Miller 2010)
+ Modest mg doses
+ Often perceived as 'SARM for advanced'

Cons

− Very marked HPG suppression (equivalent Test 200-300 mg/wk)
− Phase 1 oncology human studies only
− Sometimes marked aggression profile
− Degraded lipid profile
− Black market: RAD-140 often counterfeited

4. Stack Ostarine + Cardarine (25 mg + 20 mg/d for 8 wk) — the recomposition stack

Combines Ostarine (light anabolic) + Cardarine GW-501516 (PPARδ agonist, lipolytic and endurance). Cardarine is not a SARM but a PPARδ activator (Narkar 2008 — exercise mimetic). Popular stack for light recomposition (muscle gain + fat loss). Cardarine controversy: Mitchell 2019 raised carcinogenic risk in rodents at high doses (human extrapolation debated).

Dose / Duration

Ostarine 25 mg/d + Cardarine 10-20 mg/d for 8-10 wk. PCT Nolva 20-40 mg/d for 4 wk for Ostarine suppression. Cardarine stop 1 wk before PCT.

Target audience

Intermediate SARM users accepting cardarine risk profile, seeking a light recomposition effect, profiles without family oncological history. Informed decision.

Pros

+ Possible recomposition: mass + cutting
+ Cardarine does not suppress HPG
+ Improved endurance (useful cardio)
+ Marked lipolytic effect
+ Moderate cost

Cons

− Debated cardarine carcinogenic risk (Mitchell 2019)
− HPG suppression by Ostarine
− Black-market cardarine: highly variable quality
− Almost non-existent human cardarine studies
− Strict WADA ban

5. Stack LGD + Ostarine (10 + 25 mg/d for 8 wk) — the SARM mass stack

Combines LGD-4033 (powerful anabolic) + Ostarine (moderate anabolic, anti-catabolic). Popular stack for SARM mass cycle. Theoretical synergy on androgen receptor. Expected gains +4-6 kg lean mass with significant cumulative HPG suppression. No clinical studies of the combination; profile based on extrapolations.

Dose / Duration

LGD-4033 10 mg/d + Ostarine 25 mg/d for 8 wk. PCT Nolva 40/40/20/20 + Clomid 50/50/25/25 for 4 wk. Hepatoprotectors.

Target audience

Very advanced SARM users, seeking an alternative to injectable AAS, solid baseline liver. Informed decision accepting undocumented cumulative risks.

Pros

+ More marked potential gains (+4-6 kg)
+ Androgen receptor synergy
+ Joint preservation (Ostarine)
+ Notable strength effect
+ No injection

Cons

− Major cumulative HPG suppression
− Degraded lipid and liver profile
− No clinical studies of the combination
− Black market: variable quality of 2 products
− Demanding PCT

6. Stack RAD-140 + Ostarine (10 + 20 mg/d for 8 wk) — the "mass strength" stack

Combines RAD-140 ('test-like' anabolic + strength and aggression effect) + Ostarine (anti-catabolic, joint preservation). Stack oriented toward SARM powerlifting/strongman version. Expected gains +4-6 kg with notable strength gain. Very marked HPG suppression (equivalent Test E 200-300 mg/wk + Ostarine 25 mg).

Dose / Duration

RAD-140 10 mg/d + Ostarine 20 mg/d for 8 wk. PCT Nolva 40/40/20/20 + Clomid 50/50/25/25 for 4 wk. Continuous hepatoprotectors.

Target audience

Very advanced SARM users in strength or powerlifting phase, solid baseline, acceptance of undocumented risk profile. Not for anxious users or those with psychiatric history.

Pros

+ Record strength effect
+ Recomposition possible
+ Joint preservation (Ostarine)
+ Positive gym aggression
+ No injection

Cons

− Severe HPG suppression
− Very degraded lipid profile
− Probable ALT/AST elevations
− Sometimes excessive aggression (daily life)
− Combination human studies absent

7. S4 (Andarine) 50 mg/d for 6 wk — the "dry" SARM

S4 (Andarine) is an older SARM (Gao 2005 preclinical) with marked 'dry' effect and low aromatization. Visual effect appreciated for cutting. Major drawback: documented visual side effect (yellowish vision, night disturbances) at 50-75 mg/d, reversible on stop. Very limited human clinical studies.

Dose / Duration

S4 50 mg/d in 2 doses (morning/noon) for 6 wk. PCT Nolva 20 mg/d for 4 wk. Pause if visual disturbances appear.

Target audience

Intermediate SARM users in cutting phase, accepting transient visual disturbances, no ophthalmological history. Not for night drivers or visual-precision jobs.

Pros

+ Marked "dry" visual effect
+ Low aromatization
+ Moderate cost
+ Mass preservation in deficit
+ No DHT

Cons

− Documented visual disturbances (yellowish night vision)
− Very limited human studies
− Preclinical studies only (Gao 2005)
− Short half-life — 2 doses/day
− Black market: variable quality

8. YK-11 5-10 mg/d for 6 wk — the "myostatin inhibitor"

YK-11 is an atypical SARM with partial AR agonist mechanism and documented preclinical myostatin inhibitor (Kanno 2011, Kanno 2013). Theoretically 'hyper' anabolic effect by lifting the myostatin brake. No human studies. Liver probably more toxic than classic SARMs. Very experimental profile.

Dose / Duration

YK-11 5-10 mg/d in 2 doses (short half-life) for 6-8 wk. PCT Nolva 40/40/20/20 for 4 wk. Continuous hepatoprotectors.

Target audience

Very advanced researchers, accepting total absence of human clinical data, excellent baseline liver, close bio monitoring. Very informed decision required.

Pros

+ Unique mechanism (myostatin inhibition)
+ Powerful theoretical anabolic effect
+ Solid preclinical studies (Kanno 2011, 2013)
+ Modest doses (5-10 mg/d)
+ Marked visual effect

Cons

− No human studies
− Probably hepatotoxic (17α-methylated steroid structure)
− Unknown HPG suppression profile
− Black market: very variable
− Very unclear legal and scientific status

9. S23 10-25 mg/d for 6-8 wk — the "hard" SARM

S23 is an experimental SARM with very high AR affinity. Jones 2009 (preclinical in male rats) documented its potential as male contraceptive. Marked 'hard' and dry effect in users. Human studies absent. Severe HPG suppression and very degraded lipid profile.

Dose / Duration

S23 10-25 mg/d for 6-8 wk. PCT Nolva 40/40/20/20 + Clomid 50/50/25/25 for 4 wk.

Target audience

Very few defensible indications in 2026. Reserved for researchers accepting total absence of human data. Very poorly informed decision by default.

Pros

+ Very high AR affinity
+ Marked "dry" effect
+ Preclinical contraceptive study (Jones 2009)
+ Notable strength effect
+ No aromatization

Cons

− No human studies
− Severe HPG suppression
− Very degraded lipid profile
− Black market: unverifiable quality
− Unknown long-term risks

10. MK-677 (Ibutamoren) 25 mg/d for 12 wk — the "oral SARM" GH

MK-677 is not a SARM but an oral GH secretagogue (ghrelin mimetic, Bowers 1984, Kojima 1999). Stimulates GH and IGF-1 release via GHS-R receptor. Nass 2008 (RCT phase 2, 65 elderly subjects, 2 years) documented +1.1 kg lean mass at 25 mg/d. Often stacked with SARMs for recovery and gain quality. Marked effects on appetite, sleep and glucose.

Dose / Duration

MK-677 25 mg/d single evening dose for 8-16 wk. No specific PCT (not HPG-suppressive). Fasting glucose monitoring.

Target audience

SARM or AAS users seeking GH/IGF-1 support, improved recovery, deep sleep. Not for pre-diabetics or those with strong family oncological history.

Pros

+ No HPG suppression
+ Solid human clinical studies (Nass 2008)
+ Marked deep sleep effect
+ Improved recovery
+ Compatible with all cycles

Cons

− Strongly increased appetite (water retention)
− Disturbed fasting glucose (moderate insulin resistance)
− Early-cycle lethargy
− Elevated IGF-1 — theoretical oncological risk (Renehan 2008)
− Moderate-high cost

Final comparison

Protocol	Gains 8 wk	HPG suppression	Safety	PCT
Ostarine solo	+2-4 kg	Moderate	Best SARM	Simple
LGD-4033 solo	+3-5 kg	Marked	Medium	Medium
RAD-140 solo	+3-5 kg	Severe	Medium-low	Medium
Ostarine + Cardarine	+2-3 kg + fat loss	Moderate	Cardarine controversial	Simple
LGD + Ostarine	+4-6 kg	Severe	Medium-low	Demanding
RAD + Ostarine	+4-6 kg	Very severe	Low	Demanding
S4 (Andarine)	+1-2 kg + hardness	Moderate	Visual disturbances	Simple
YK-11	+2-4 kg (?)	Unknown	Hepatic questionable	Medium
S23	+3-5 kg (?)	Severe	Very experimental	Demanding
MK-677	+1-2 kg + recovery	None	Good apart from glucose	None

FAQ

Do SARMs really suppress the HPG axis?: Yes, at effective doses. The 'non-suppressive SARM' myth is widely spread on internet but contradicted by clinical data. Dalton 2011 documents a testosterone decrease as early as 3 mg/d of Ostarine; at 25 mg/d (bodybuilding dose), suppression reaches 30-50% of baseline. Basaria 2013 confirms dose-dependent suppression on LGD-4033. Bhasin 2009 (SARM function-promoting review) specifies that all AR agonists at anabolic doses suppress the HPG axis via hypothalamic feedback. Practical consequence: PCT required for all effective SARM cycles.
What PCT after a SARMs cycle?: Depends on the SARM and dose. For Ostarine 25 mg/d for 8 wk: Nolvadex 20 mg/d for 4 wk suffices in most. For LGD-4033 10 mg/d for 8 wk or RAD-140 10 mg/d for 8 wk: Nolvadex 40/40/20/20 mg/d for 4 wk, sometimes + Clomid 50/50/25/25 mg/d in parallel. For SARMs stacks (LGD + Ostarine or RAD + Ostarine): moderate AAS-type PCT (Nolva + Clomid 4 wk). Bloodwork total T + LH 6 wk post-PCT to confirm recovery. hCG very rarely needed on SARMs cycles (HPG axis less deeply suppressed than on heavy AAS stacks).
Are SARMs safer than AAS?: Not demonstrated in 2026. SARMs long-term safety profile is largely unknown: phase 2/3 human studies are limited (Dalton 2011 the most solid, over 12 wk). AAS are disliked but well-studied (Bhasin 1996, Hartgens 2004, HAARLEM Smit 2021/2022). SARMs accumulate risks: (1) highly variable market quality (frequent counterfeits — Magnolini 2022), (2) documented hepatotoxicity (elevated ALT/AST on RAD-140 and LGD-4033), (3) degraded lipid profile, (4) absent long-term data. 'Safer' argument often rests on lower dose vs AAS, not on clinical evidence.
Black-market SARMs: how to verify quality?: Difficult. Magnolini 2022 (spectrometric analysis of European AAS products) documents 40-60% non-compliant products; for SARMs, recent analyses (Almeida 2021, Van Wagoner 2017 USA) suggest 50-70% out-of-spec products. Risk-reduction strategies: (1) Third-party analysis (HPLC, MS) by labs like JANO, AnalyticalGroup, Aramo (~$50-100/sample). (2) Sources with public batch testing and verifiable reviews. (3) Distrust of 'generic' products without certificate. (4) For personal use: test on first SARMs cycle with mid-cycle total T bloodwork to confirm real activity. No absolute guarantee.
SARMs and anti-doping: risk?: High. All SARMs are on the WADA list (S1.2 category — other anabolic agents) banned in and out of competition. Detection: Ostarine, LGD-4033, RAD-140 detectable up to 2-6 months post-stop depending on dose and test (Solomon 2019). Documented cases of 'accidental' contamination via SARMs-contaminated supplements (growing problem 2018-2024). Tested-sport athletes must avoid even non-batch-tested supplements. Variable civil legal status: in many regions, SARMs are in a gray zone (neither MA nor cosmetic authorization), marketed as 'research chemicals' with 'not for human consumption' label.
Is an AI needed on a SARMs cycle?: Rarely. Most SARMs don't aromatize (no E2 conversion). However, endogenous testosterone early in cycle may still aromatize; and certain SARMs (Ostarine in particular) may indirectly modulate SHBG. Recommendation: no routine AI on SARMs cycles. If elevated E2 symptoms (nascent gynecomastia, retention), E2 bloodwork and anastrozole 0.25 mg E3D as needed. On SARM stop, E2 may transiently rebound — manage during PCT if necessary.
Do SARMs preserve mass during cutting?: Yes, modestly. Ostarine 12.5-25 mg/d for 8 wk in caloric deficit preserves lean mass better than without SARM, by direct anti-catabolic effect on muscle (mechanism close to AAS without peripheral androgenicity). Solomon 2019 review documents Ostarine anti-catabolic effect in sarcopenia/cachexia. On athlete at -400 kcal/d for 8 wk: mass preservation +0.5 to +1 kg vs natural or +1-2 kg vs without SARM. Effect more modest than Test E + Anavar cycle but without injection, null androgenic profile, and moderate cost.
Is MK-677 dangerous for diabetes?: To monitor. MK-677 increases GH and IGF-1, which may induce moderate insulin resistance — Nass 2008 documents elevated fasting glucose in elderly subjects on MK-677 at 25 mg/d. Reversible effect on stop. Recommendations: fasting glucose monitoring at W4, W8, W12; HbA1c at start and end of cycle. Contraindicated in: pre-diabetics (HbA1c >5.7%), type 2 diabetics, strong family history. Possible in subject with normal baseline glucose with monitoring. Precaution: no fast carbohydrates in evening, exercise maintained for insulin sensitivity.